| __timestamp | Ascendis Pharma A/S | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 10337679 |
| Thursday, January 1, 2015 | 9415000 | 18187286 |
| Friday, January 1, 2016 | 11504000 | 24758063 |
| Sunday, January 1, 2017 | 13482000 | 23666957 |
| Monday, January 1, 2018 | 25057000 | 30099855 |
| Tuesday, January 1, 2019 | 48473000 | 64947625 |
| Wednesday, January 1, 2020 | 76669000 | 186363444 |
| Friday, January 1, 2021 | 160180000 | 272611040 |
| Saturday, January 1, 2022 | 221227000 | 358782000 |
| Sunday, January 1, 2023 | 264410000 | 409864000 |
| Monday, January 1, 2024 | 284545000 |
Igniting the spark of knowledge
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Intra-Cellular Therapies, Inc. and Ascendis Pharma A/S from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. saw a staggering 3,865% increase in SG&A expenses, peaking in 2023. Ascendis Pharma A/S, while also experiencing growth, expanded its SG&A expenses by approximately 4,110% during the same timeframe. This trend highlights the escalating costs associated with scaling operations and market expansion. Notably, both companies showed significant jumps in expenses post-2019, reflecting strategic investments in marketing and administrative capabilities. As these companies continue to innovate, understanding their cost structures provides valuable insights into their operational strategies and financial health.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Operational Costs Compared: SG&A Analysis of GSK plc and Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Ascendis Pharma A/S vs Dynavax Technologies Corporation
Comparing SG&A Expenses: Ascendis Pharma A/S vs Xencor, Inc. Trends and Insights